title: Immunomodulating antibodies and drugs for the treatment of hematological malignancies.
abstract: The aim of cancer immunotherapy is to induce immune cells to kill tumor and promote immunological memory that protects against tumor recurrence. Most current immunotherapies, such as monoclonal antibodies (mAb), target the tumor cells directly. Advances in our understanding of the immune system such as the role of co-stimulatory and co-inhibitory receptors, and the advent of new immunomodulatory agents provide new opportunities to target the immune system and enhance anti-tumor immune responses. These promising agents include immunomodulating mAbs, Toll-like receptor agonists, IMiDs, and cytokines. In this review, we discuss the current results of immunomodulating agents in the treatment of hematological malignancies and propose applications that include targeting of the innate and adaptive immune systems as well as combinations with tumor-specific mAbs.
authors.affiliation: Service d'Hématologie Clinique & INSERM U917, Centre Hospitalier Universitaire de Rennes, Rennes, France.
authors.forename: Roch
authors.initials: R
authors.lastname: Houot
authors.forename: Holbrook
authors.initials: H
authors.lastname: Kohrt
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Goldstein
authors.forename: Ronald
authors.initials: R
authors.lastname: Levy
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000378:metabolism / Q000627:therapeutic use*; D007167:Immunotherapy
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D007155:Immunologic Factors